Drug Trial Radar · NCT05329298
A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 21, 2021
Primary completion
Jun 30, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of BPI-361175 tablets in patients with advanced solid tumors including advanced Non-small cell Lung cancer (NSCLC).This is a three-stage study, consisting of Phase Ia dose escalation, Phase Ib dose expansion and pivotal Phase II Study. The pivotal Phase II study will be designed based on data generated from the Phase I studies.
Conditions
- Non-small Cell Lung Cancer
Interventions
BPI-361175Drug
Subjects will receive BPI-361175 until disease progression
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: The adverse events (AEs)Time frame: Through the Phase I, approximately 24 months
- Phase I: Determine the recommended Phase II dose (RP2D)Time frame: Through the Phase I, approximately 24 months
- Phase II: the objective response rate (ORR)Time frame: Through the Phase II, approximately 24 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Hunan cancer hospital
Changsha, Hunan, China · Recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
the First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.